Atara Biotherapeutics, Inc. announced on December 30, 2025, a reduction in potential milestone payments from Pierre Fabre from $40 million to $31 million, while acquiring the opportunity for an additional $15 million payment upon achieving a commercial milestone. This agreement modifies their earlier commercialization contract dated October 31, 2023.